^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NCAM1 positive

    i
    Other names: NCAM1, CD56, NCAM, Neural cell adhesion molecule 1
    Entrez ID:
    4684
    Related biomarkers:
    Expression
    11ms
    Correlation between conventional karyotype, interphase FISH and immunophenotype in risk stratification of newly diagnosed plasma cell myeloma: An observational study. (PubMed, Med J Armed Forces India)
    Immunophenotypic antigens positive and negative expressions are associated with high-risk genetic abnormalities and advanced clinical stages of PCM. IEC/2017/230, AFMC, Pune.
    Observational data • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD28 (CD28 Molecule) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule)
    |
    Chr t(11;14) • Chr t(4;14) • NCAM1 expression • PTPRC expression • NCAM1 positive
    12ms
    CD30- and CD56-positive atypical intravascular lymphocytes of the uterine cervix, mimicking intravascular lymphoma: A case report and review of the literature. (PubMed, J Clin Exp Hematop)
    This condition is characterized by CD30+ and CD3+ or CD4+ atypical T-cells and is often associated with trauma and chronic inflammation. This case highlights atypical intravascular lymphoid cells of the uterine cervix that are positive for CD30 and CD56 and can mimic IVL.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    TNFRSF8 positive • NCAM1 positive
    1year
    Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    apalutamide
    1year
    Desmoplastic Small Round Cell Tumor in a Young Adult: A Case Report Highlighting Diagnostic Challenges and Treatment Approaches. (PubMed, Cureus)
    The patient was placed on a regimen alternating the combination of vincristine, doxorubicin, and cyclophosphamide for one week and ifosfamide and etoposide for the next. It also discusses the complexity and challenges of managing this rare aggressive malignancy. This case report also addresses the necessity for advanced research into targeted therapies and optimized strategies in the treatment to help improve the survival rates and quality of life for patients with DSRCT.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine
    1year
    Evaluation of CD56 and CD117 Double-positive as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis. (PubMed, Turk J Haematol)
    The high cytogenetic risk was found to bean independent predictor of shorter OS (p>0.001). The study's findings revealed that CD56 and CD117 double- positive MM patients had poorer prognosis, lower ORR, shorter OS, and higher mortality.
    Retrospective data • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NCAM1 (Neural cell adhesion molecule 1)
    |
    KIT expression • NCAM1 positive
    over1year
    The RTK-RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS::ERG. (PubMed, Blood Sci)
    Transcriptome analysis revealed enrichment of the phosphatidylinositol-3-kinase-Akt (PI3K-Akt), mitogen-activated protein kinase (MAPK), and RAS signaling pathways and upregulation of BCL2, the target of venetoclax, in FUS::ERG AML compared to RUNX1::RUNX1T1 AML, a more common AML subtype with good prognosis...Allogeneic hematopoietic stem cell transplantation failed to improve outcomes. Overall, the high incidence of RTK-RAS pathway mutations and high expression of BCL2 may indicate promising therapeutic targets in this high-risk AML subset.
    Journal • IO biomarker
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NCAM1 (Neural cell adhesion molecule 1) • FUS (FUS RNA Binding Protein)
    |
    KRAS mutation • RAS mutation • BCL2 overexpression • BCL2 expression • NCAM1 positive
    |
    Venclexta (venetoclax)
    over1year
    Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Jan 2027 | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    apalutamide
    over1year
    Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma. (PubMed, Front Immunol)
    In HCC patients, ILT2 is a signature molecule for cancerous CD56dim NK cells with impaired cytolytic capacity. The MIF-CXCR4 interaction is associated with ILT2 induction on CD56dim NK cells and ILT2 serves as a target for functional NK cell restoration.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • MIF (Macrophage Migration Inhibitory Factor)
    |
    NCAM1 positive
    over1year
    A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine. (PubMed, Gan To Kagaku Ryoho)
    In August Year X-1, she developed molecular relapse and was started on tamibarotene(Am80). She died of gastrointestinal hemorrhage. This is considered a valuable case for accumulating information on the treatment of CD56-positive APL resistant to ATRA and ATO.
    Journal • Combination therapy
    |
    RARA (Retinoic Acid Receptor Alpha) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    Venclexta (venetoclax) • azacitidine • Amnolake (tamibarotene)
    almost2years
    Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry. (PubMed, Fetal Pediatr Pathol)
    CD56 is a potential negative prognostic marker. These findings suggest that CD30 and CD56 targeted therapies could be potential therapeutic targets for LBL patients.
    Retrospective data • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • NCAM1 (Neural cell adhesion molecule 1)
    |
    TNFRSF8 expression • NCAM1 expression • NCAM1 positive
    2years
    Diagnostic Challenges in the Leukemia Phase of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Involvement: A Clinical and Pathological Study (ASH 2023)
    Only one cycle of decitabine + CAG was given and 5 months later, the disease progressed to the leukemia phase...The latter case had ASXL1 and TET2 mutations detected by NGS analysis, achieved complete remission after receiving venetoclax + azacitidine for one cycle, followed by intermittent venoclax +demethylation agent or low-dose chemotherapy maintenance treatment and live for more than two years now... BPDCN without skin lesions is clinically rare, and its diagnosis is challenging. Comprehensive immunophenotyping and cautious interpretation of immunohistochemistry results such as dim lysozyme expression are crucial. Venetoclax-containing regimens have shown promising therapeutic effects.
    Clinical
    |
    TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD36 (thrombospondin receptor) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NRP1 (Neuropilin 1) • SPN (Sialophorin) • TCL1A (TCL1 Family AKT Coactivator A) • ANPEP (Alanyl Aminopeptidase, Membrane) • CLEC4C (C-Type Lectin Domain Family 4 Member C) • MPO (Myeloperoxidase)
    |
    TP53 mutation • ASXL1 mutation • TET2 mutation • CD123 positive • NCAM1 expression • CD123 expression • CD4 expression • IDH2 mutation + TP53 mutation • IL3RA positive • NCAM1 positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    2years
    Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome (ASH 2023)
    Cytoplasmic cyclin D1 expression may be related to lack of cyclin D1 protein degradation by a defective UBA1 gene product. Our results suggest that defective UBA1 and autoinflammation pose an increased risk for developing MGUS or multiple myeloma.
    Clinical • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • IRF4 (Interferon regulatory factor 4) • CD81 (CD81 Molecule)
    |
    CD20 positive • CD20 expression • CD19 expression • CCND1 expression • SDC1 positive • NCAM1 positive